Clinical Trials

Retrospective and ongoing prospective clinical trials show strong evidence for the VERIDAPT DX™ biomarker’s clinical effectiveness. 

VERIDAPT DX responds to a critical need in oncology for an early-stage tool to personalize treatment based on a patient’s individual response to a chosen drug regimen.

VERIDAPT DX has been rigorously tested in prospective and retrospective clinical studies. Once fully validated, the biomarker will help oncologists accurately predict which treatment will be effective for individual patients during neoadjuvant therapy.

Our ultimate goal is to personalize breast cancer treatments. If validated, this test has the potential to accurately predict which treatment will be effective for an individual patient.

Dr. Foluso Ademuyiwa

St Louis Missouri, Professor of Medicine, Division of Oncology, Section of Breast Oncology, Washington University School of Medicine, Co-Chair of BREVITY Steering Committee



Phase 1 results (reported in JNCI Cancer Spectrum) demonstrated a very strong capability to predict therapy efficacy during treatment (Negative Predictive Value >93%). Phase 2, which will focus on validating Phase 1 results, is under way in seven countries.


In collaboration with Clinical Trials Ireland, SHAMROCK is an adaptive trial focused on high-risk HER2-positive breast cancer patients being treated with the monoclonal antibody drugs trastuzumab and pertuzumab. The goal is to use the VERIDAPT DX platform to identify super-responders and adjust treatments to minimize exposure to this highly effective, but toxic, class of drugs.


Led by scientists at Cancer Research UK and the University of Birmingham, the Response to Optimal Selection of neoadjuvant Chemotherapy in Operable breast cancer study is evaluating the use of genetic markers to predict patients’ response to different combinations of chemotherapy. The VERIDAPT DX platform is being deployed in a substudy. Results  may be ready for publication by the end of 2024

 In collaboration with:

Research Opportunities

Working with a global network of researchers and clinicians, Rna Diagnostics expects to achieve more significant clinical milestones in coming months. While our current focus is on validating VERIDAPT DX for early-stage breast cancer, we welcome opportunities to work with cancer researchers studying other solid tumor types.